These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 17691110

  • 1. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.
    Int J Cancer; 2007 Dec 15; 121(12):2606-14. PubMed ID: 17691110
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
    Kłosowska-Wardęga A, Hasumi Y, Åhgren A, Heldin CH, Hellberg C.
    Melanoma Res; 2011 Feb 15; 21(1):57-65. PubMed ID: 20975605
    [Abstract] [Full Text] [Related]

  • 3. The effects of tumor-derived platelet-derived growth factor on vascular morphology and function in vivo revealed by susceptibility MRI.
    Robinson SP, Ludwig C, Paulsson J, Ostman A.
    Int J Cancer; 2008 Apr 01; 122(7):1548-56. PubMed ID: 18033683
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ.
    Clin Cancer Res; 2003 Dec 15; 9(17):6534-44. PubMed ID: 14695158
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T.
    Cancer; 2005 May 01; 103(9):1800-9. PubMed ID: 15786421
    [Abstract] [Full Text] [Related]

  • 6. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.
    Blood; 2013 Jun 27; 121(26):5192-202. PubMed ID: 23632889
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
    McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM.
    J Clin Invest; 2007 Aug 27; 117(8):2114-22. PubMed ID: 17641778
    [Abstract] [Full Text] [Related]

  • 8. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
    Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.
    Am J Obstet Gynecol; 2008 Apr 27; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
    [Abstract] [Full Text] [Related]

  • 9. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R.
    J Cell Physiol; 2006 Jul 27; 208(1):220-8. PubMed ID: 16575905
    [Abstract] [Full Text] [Related]

  • 10. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA.
    Nature; 2008 Dec 11; 456(7223):809-13. PubMed ID: 18997771
    [Abstract] [Full Text] [Related]

  • 11. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
    Tsioumpekou M, Cunha SI, Ma H, Åhgren A, Cedervall J, Olsson AK, Heldin CH, Lennartsson J.
    Theranostics; 2020 Dec 11; 10(3):1122-1135. PubMed ID: 31938055
    [Abstract] [Full Text] [Related]

  • 12. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P.
    FASEB J; 2004 Feb 11; 18(2):338-40. PubMed ID: 14657001
    [Abstract] [Full Text] [Related]

  • 13. Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma.
    Suzuki S, Heldin CH, Heuchel RL.
    BMC Cancer; 2007 Dec 12; 7():224. PubMed ID: 18076756
    [Abstract] [Full Text] [Related]

  • 14. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K, Hanahan D.
    J Clin Oncol; 2005 Feb 10; 23(5):939-52. PubMed ID: 15557593
    [Abstract] [Full Text] [Related]

  • 15. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 16. Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells.
    Pirraco A, Coelho P, Rocha A, Costa R, Vasques L, Soares R.
    J Cell Biochem; 2010 Oct 01; 111(2):433-41. PubMed ID: 20518073
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of platelet-derived growth factor receptor-β signaling mediated by integrin-associated MFG-E8.
    Motegi S, Garfield S, Feng X, Sárdy M, Udey MC.
    Arterioscler Thromb Vasc Biol; 2011 Nov 01; 31(11):2653-64. PubMed ID: 21868707
    [Abstract] [Full Text] [Related]

  • 18. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM.
    Cancer Res; 2009 May 15; 69(10):4527-36. PubMed ID: 19401451
    [Abstract] [Full Text] [Related]

  • 19. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
    Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E.
    Cancer Res; 2005 Feb 01; 65(3):957-66. PubMed ID: 15705896
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE.
    Clin Cancer Res; 2005 Jan 01; 11(1):306-14. PubMed ID: 15671560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.